Oncology Institute Inc’s recently made public that its Director M33 Growth I L.P. unloaded Company’s shares for reported $2.05 million on Jun 05 ’25. In the deal valued at $3.05 per share,673,676 shares were sold. As a result of this transaction, M33 Growth I L.P. now holds 13,950,557 shares worth roughly $53.29 million.
Then, M33 Growth I L.P. sold 76,324 shares, generating $232,788 in total proceeds. Upon selling the shares at $3.05, the Director now owns 1,272,724 shares.
Before that, Hively Brad sold 1,976,137 shares. Oncology Institute Inc shares valued at $5,672,106 were divested by the Director at a price of $2.87 per share. As a result of the transaction, Hively Brad now holds 603,501 shares, worth roughly $2.31 million.
Noble Capital Markets initiated its Oncology Institute Inc [TOI] rating to an Outperform in a research note published on July 23, 2025; the price target was $8. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. BTIG Research began covering TOI with “Buy” recommendation on May 15, 2025.
Price Performance Review of TOI
On Tuesday, Oncology Institute Inc [NASDAQ:TOI] saw its stock fall -5.45% to $3.82. Over the last five days, the stock has lost -7.06%. Oncology Institute Inc shares have risen nearly 967.04% since the year began. Nevertheless, the stocks have risen 1136.25% over the past one year. While a 52-week high of $4.50 was reached on 08/07/25, a 52-week low of $0.13 was recorded on 01/10/25.
Levels Of Support And Resistance For TOI Stock
The 24-hour chart illustrates a support level at 3.68, which if violated will result in even more drops to 3.53. On the upside, there is a resistance level at 4.04. A further resistance level may holdings at 4.25.
How much short interest is there in Oncology Institute Inc?
A steep rise in short interest was recorded in Oncology Institute Inc stocks on 2025-07-31, dropping by -0.27 million shares to a total of 5.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 5.77 million shares. There was a decline of -5.0%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 14, 2022 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
